• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparison of markers of coagulation activation in patients under oral anticoagulation at different levels.

作者信息

van Wersch J W, van Mourik-Alderliesten C H, Coremans A

机构信息

Haematological Laboratory, De Wever Ziekenhuis, Heerlen, The Netherlands.

出版信息

Eur J Clin Chem Clin Biochem. 1992 Aug;30(8):461-6. doi: 10.1515/cclm.1992.30.8.461.

DOI:10.1515/cclm.1992.30.8.461
PMID:1445959
Abstract

Three groups of patients receiving oral anticoagulation treatment were evaluated. The groups consisted of patients with mechanical heart valve prosthesis (n = 60), patients after coronary bypass graft surgery (n = 60) and patients using oral anticoagulation after deep venous thrombosis or pulmonary embolism (n = 60). The patient groups were subdivided into three groups of 20 patients, each group receiving different levels of oral anticoagulation as indicated by the international normalized ratio (INR). Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and fibrin monomers were determined as coagulation activation makers. The prothrombin fragments 1 + 2 were INR dependent in all groups whereas the thrombin-antithrombin III values were only INR dependent in the group of patients with mechanical heart valve prosthesis. For fibrin monomers no correlation with the INR levels could be found. These results indicate that prothrombin fragment 1 + 2 is the only laboratory quantity of the three, which provides a suitable index of low thrombin activity during anticoagulation therapy.

摘要

相似文献

1
Comparison of markers of coagulation activation in patients under oral anticoagulation at different levels.
Eur J Clin Chem Clin Biochem. 1992 Aug;30(8):461-6. doi: 10.1515/cclm.1992.30.8.461.
2
Determination of markers of coagulation activation and reactive fibrinolysis in patients with mechanical heart valve prosthesis at different intensities of oral anticoagulation.不同口服抗凝强度下机械心脏瓣膜置换患者凝血激活和反应性纤溶标志物的测定
Blood Coagul Fibrinolysis. 1992 Apr;3(2):183-6. doi: 10.1097/00001721-199204000-00007.
3
Markers of in vivo activation of coagulation. Interrelationships change with intensity of oral anticoagulation.
Am J Clin Pathol. 1996 Mar;105(3):293-7. doi: 10.1093/ajcp/105.3.293.
4
[Prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complex(TAT) and thrombophilia parameters in orally anticoagulated patients with inferior vena cava filters].口服抗凝治疗的下腔静脉滤器置入患者的凝血酶原片段1+2(F1+2)、凝血酶-抗凝血酶III复合物(TAT)及血栓形成倾向参数
Wien Med Wochenschr. 1993;143(5):95-8.
5
Influence of long term oral anticoagulants upon prothrombin fragment 1 + 2, thrombin-antithrombin III complex and D-Dimer levels in patients affected by proximal deep vein thrombosis.长期口服抗凝剂对近端深静脉血栓形成患者凝血酶原片段1+2、凝血酶-抗凝血酶III复合物及D-二聚体水平的影响
Thromb Haemost. 1993 Apr 1;69(4):302-5.
6
Coagulation activation and reactive fibrinolysis in patients receiving oral anticoagulation after total hip or knee replacement.全髋关节或膝关节置换术后接受口服抗凝治疗患者的凝血激活与反应性纤维蛋白溶解
Blood Coagul Fibrinolysis. 1994 Aug;5(4):605-8.
7
High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.凝血酶原的高F1.2片段、凝血酶 - 抗凝血酶III复合物(TAT)以及可溶性纤维蛋白血浆水平表明,在使用rt - PA进行局部区域溶栓治疗期间会诱发高凝状态。
Thromb Res. 1994 Jan 15;73(2):109-15. doi: 10.1016/0049-3848(94)90085-x.
8
Effects of warfarin on markers of hypercoagulability in patients with heart failure.华法林对心力衰竭患者高凝状态标志物的影响。
Am Heart J. 1997 Jul;134(1):27-36. doi: 10.1016/s0002-8703(97)70103-0.
9
[Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].[冠状动脉Palmaz-Schatz支架植入后抗凝血酶III、凝血酶原片段1+2及凝血酶-抗凝血酶III复合物的变化]
Z Kardiol. 1995 Jan;84(1):22-9.
10
Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants.足月儿体外膜肺氧合期间凝血系统的激活
J Pediatr. 1996 Aug;129(2):264-8. doi: 10.1016/s0022-3476(96)70252-4.